Completed PHASE3 INTERVENTIONAL 2-arm NCT01637454

TYPE 2 HEPATORENAL SYNDROME (Type2 HRS)

NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Conditions Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS

Interventions Noradrenaline Terlipressin

Updated 6 times since 2017 Last updated: Jul 10, 2012 Started: Jan 31, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Safety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRS and is currently completed. Post Graduate Institute of Medical Education and Research, Chandigarh leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Post Graduate Institute of Medical Education and Research, Chandigarh

Data source: PIMERIndia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chandigarh, India